Reuters logo
4 个月前
BRIEF-FDA accepts for priority review Bristol-Myers' application for Opdivo in previously treated metastatic colorectal cancer
2017年4月4日 / 晚上8点38分 / 4 个月前

BRIEF-FDA accepts for priority review Bristol-Myers' application for Opdivo in previously treated metastatic colorectal cancer

April 4 (Reuters) - Bristol-myers Squibb Co

* U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb's application for Opdivo (nivolumab) in previously treated DMMR or MSI-H metastatic colorectal cancer

* Bristol-Myers Squibb Co - FDA granted application priority review, and FDA action date is August 2, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below